Nitrogen uptake by winter wheat (Triticum aestivum L.) depending on fertilizer application

The influence of the injection of nitrogen fertilizers with the CULTAN system (Controlled Uptake Long Term Ammonium Nutrition) on nitrogen uptake by winter wheat (Triticum aestivum L.) was observed at small-plot field experiments under conditions of the Czech Republic (central Europe) during 2007–2013. The CULTAN system consisting in the injection of all the nitrogen in one dose was compared with conventional broadcast surface fertilization which is carried out in three partial nitrogen doses. The total nitrogen dosage was 150 kg N.ha−1. If the CULTAN fertilization was carried out at the beginning of tillering of winter wheat (BBCH 22) instead of at the end of tillering (BBCH 29), the CULTAN-treated winter wheat did not suffer from nitrogen deficiency at the BBCH 45 (boot stage) and BBCH 51 (beginning of heading) growth stages. Nitrogen utilization efficiency and biomass production efficiency were significantly higher with the CULTAN treatment compared to the conventional fertilization whereas nitrogen uptake efficiency tended toward lower values with the CULTAN treatment. Nitrogen use efficiency (NUE), post-heading nitrogen uptake, the contribution of nitrogen translocation to the total nitrogen in grain, the partial factor productivity of nitrogen as well as grain yield were not significantly influenced by the CULTAN system. Prolonged nitrogen uptake from the soil with the CULTAN treatment resulting in delayed plant senescence was not confirmed. Neither an application of sulphur-containing fertilizer nor the increased dosage of nitrogen (200 kg N.ha−1) positively affected the studied parameters

RADIOLUCENT COMPOSITES PROVIDING HIGH RESISTANCE AGAINST STERILIZATION DECOMPOSITION

We present a study of radiolucent composite materials for use in medicine, providing suitable mechanical properties and high resistance against sterilization decomposition. The composites are composed of carbon (C), aramid or glass (R-glass) fabrics embedded in polydimethylsiloxane (PDMS), polyetheretherketone (PEEK) or polyphenylene sulfide (PPS) matrix. The effect of multiple steam sterilization processes on degrading the mechanical properties, structural integrity and hydrolytic decomposition of the composites was verified. The radiolucency of the composites was also investigated. The mechanical performance of ARAMID/PDMS composite is strongly influenced by the sterilization technique that is applied. The mechanical behavior of R-glass/PDMS composite during steam sterilization is negatively influenced by its porosity. The relatively high porosity of C/PDMS composite may lead to lower ultimate bending strength values, but in general its mechanical behavior is influenced only at a low rate by steam sterilization. On the basis of our analyses, we can state that both C/PEEK and C/PPS composites are good candidates for application as radiolucent materials providing resistance against sterilization decomposition

Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.

OBJECTIVES: The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The secondary objective is to investigate the efficacy and safety of dexamethasone 20 mg versus dexamethasone 6 mg. The exploratory objective of this study is to assess long-term consequences on mortality and quality of life at 180 and 360 days. TRIAL DESIGN: REMED is a prospective, phase II, open-label, randomised controlled trial testing superiority of dexamethasone 20 mg vs 6 mg. The trial aims to be pragmatic, i.e. designed to evaluate the effectiveness of the intervention in conditions that are close to real-life routine clinical practice. PARTICIPANTS: The study is multi-centre and will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic. INCLUSION CRITERIA: Subjects will be eligible for the trial if they meet all of the following criteria: 1. Adult (≥18 years of age) at time of enrolment; 2. Present COVID-19 (infection confirmed by RT-PCR or antigen testing); 3. Intubation/mechanical ventilation or ongoing high-flow nasal cannula (HFNC) oxygen therapy; 4. Moderate or severe ARDS according to Berlin criteria:  • Moderate - PaO2/FiO2 100-200 mmHg;  • Severe - PaO2/FiO2 < 100 mmHg; 5. Admission to ICU in the last 24 hours. EXCLUSION CRITERIA: Subjects will not be eligible for the trial if they meet any of the following criteria: 1. Known allergy/hypersensitivity to dexamethasone or excipients of the investigational medicinal product (e.g. parabens, benzyl alcohol); 2. Fulfilled criteria for ARDS for ≥14 days at enrolment; 3. Pregnancy or breastfeeding; 4. Unwillingness to comply with contraception measurements from enrolment until at least 1 week after the last dose of dexamethasone (sexual abstinence is considered an adequate contraception method); 5. End-of-life decision or patient is expected to die within next 24 hours; 6. Decision not to intubate or ceilings of care in place; 7. Immunosuppression and/or immunosuppressive drugs in medical history:  a) Systemic immunosuppressive drugs or chemotherapy in the past 30 days;  b) Systemic corticosteroid use before hospitalization;  c) Any dose of dexamethasone during the present hospital stay for COVID-19 for ≥5 days before enrolment;  d) Systemic corticosteroids during present hospital stay for conditions other than COVID-19 (e.g. septic shock); 8. Current haematological or generalized solid malignancy; 9. Any contraindication for corticosteroid administration, e.g.  • intractable hyperglycaemia;  • active gastrointestinal bleeding;  • adrenal gland disorders;  • presence of superinfection diagnosed with locally established clinical and laboratory criteria without adequate antimicrobial treatment; 10. Cardiac arrest before ICU admission; 11. Participation in another interventional trial in the last 30 days. INTERVENTION AND COMPARATOR: Dexamethasone solution for injection/infusion is the investigational medicinal product as well as the comparator. The trial will assess two doses, 20 mg (investigational) vs 6 mg (comparator). Patients in the intervention group will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. Patients in the control group will receive dexamethasone 6 mg day 1-10. All authorized medicinal products containing dexamethasone in the form of solution for i.v. injection/infusion can be used. MAIN OUTCOMES: Primary endpoint: Number of ventilator-free days (VFDs) at 28 days after randomisation, defined as being alive and free from mechanical ventilation. SECONDARY ENDPOINTS: a) Mortality from any cause at 60 days after randomisation; b) Dynamics of inflammatory marker (C-Reactive Protein, CRP) change from Day 1 to Day 14; c) WHO Clinical Progression Scale at Day 14; d) Adverse events related to corticosteroids (new infections, new thrombotic complications) until Day 28 or hospital discharge; e) Independence at 90 days after randomisation assessed by Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days through telephone structured interviews using the Barthel Index. RANDOMISATION: Randomisation will be carried out within the electronic case report form (eCRF) by the stratified permuted block randomisation method. Allocation sequences will be prepared by a statistician independent of the study team. Allocation to the treatment arm of an individual patient will not be available to the investigators before completion of the whole randomisation process. The following stratification factors will be applied: • Age <65 and ≥ 65; • Charlson Comorbidity index (CCI) <3 and ≥3; • CRP <150 mg/L and ≥150 mg/L • Trial centre. Patients will be randomised in a 1 : 1 ratio into one of the two treatment arms. Randomisation through the eCRF will be available 24 hours every day. BLINDING (MASKING): This is an open-label trial in which the participants and the study staff will be aware of the allocated intervention. Blinded pre-planned statistical analysis will be performed. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The sample size is calculated to detect the difference of 3 VFDs at 28 days (primary efficacy endpoint) between the two treatment arms with a two-sided type I error of 0.05 and power of 80%. Based on data from a multi-centre randomised controlled trial in COVID-19 ARDS patients in Brazil and a multi-centre observational study from French and Belgian ICUs regarding moderate to severe ARDS related to COVID-19, investigators assumed a standard deviation of VFD at 28 days as 9. Using these assumptions, a total of 142 patients per treatment arm would be needed. After adjustment for a drop-out rate, 150 per treatment arm (300 patients per study) will be enrolled. TRIAL STATUS: This is protocol version 1.1, 15.01.2021. The trial is due to start on 2 February 2021 and recruitment is expected to be completed by December 2021. TRIAL REGISTRATION: The study protocol was registered on EudraCT No.:2020-005887-70, and on December 11, 2020 on ClinicalTrials.gov (Title: Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19 (REMED)) Identifier: NCT04663555 with a last update posted on February 1, 2021. FULL PROTOCOL: The full protocol (version 1.1) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the standard formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol

Efficiency of extractants to release As, Cd and Zn from main soil compartments

Various soil extraction methods were developed for the determination of total and/or plant-available concentrations of potentially toxic elements. In this experiment, four single extraction procedures (aqua regia, HNO$_3$, acetic acid, DTPA) were tested for the determination of extractable contents of As, Cd and Zn. 35 soils differing in their physicochemical properties and in total element contents were used in this experiment. Extractability of elements from soil samples varied following the individual elements and/or extraction agents used. The strong acids were not able to release the elements tightly bound into the silicate sample matrix. However, such techniques remain utilizable for the approximate determination of “pseudototal” element contents in soil, especially if soil samples are affected by anthropogenic contamination. The concentrations of As, Cd, and Zn determined in soil extracts by both mineral and organic acids covered in most cases the element portion representing more than one soil element fraction determined using SM&T sequential extraction procedure. Solutions of acetic acid and DTPA were able to release a part of the element fraction bound in Fe/Mn oxides and organic matter of soil sample. Arsenic represents an exception because it is not released by DTPA

NMDA Receptor Opening and Closing—Transitions of a Molecular Machine Revealed by Molecular Dynamics

We report the first complete description of the molecular mechanisms behind the transition of the N-methyl-d-aspartate (NMDA) receptor from the state where the transmembrane domain (TMD) and the ion channel are in the open configuration to the relaxed unliganded state where the channel is closed. Using an aggregate of nearly 1 &micro;s of unbiased all-atom implicit membrane and solvent molecular dynamics (MD) simulations we identified distinct structural states of the NMDA receptor and revealed functionally important residues (GluN1/Glu522, GluN1/Arg695, and GluN2B/Asp786). The role of the &ldquo;clamshell&rdquo; motion of the ligand binding domain (LBD) lobes in the structural transition is supplemented by the observed structural similarity at the level of protein domains during the structural transition, combined with the overall large rearrangement necessary for the opening and closing of the receptor. The activated and open states of the receptor are structurally similar to the liganded crystal structure, while in the unliganded receptor the extracellular domains perform rearrangements leading to a clockwise rotation of up to 45 degrees around the longitudinal axis of the receptor, which closes the ion channel. The ligand-induced rotation of extracellular domains transferred by LBD&ndash;TMD linkers to the membrane-anchored ion channel is responsible for the opening and closing of the transmembrane ion channel, revealing the properties of NMDA receptor as a finely tuned molecular machine

Wpływ kadmu i cynku na metabolizm szpinaku

Changes in metabolism of spinach (Spinacia oleracea L., 'Matador' cv.) plants exposed to stress caused by two heavy metals: cadmium and zinc were studied. The distribution of these elements in biomass (in root, leaf blade, petiole), chlorophyll content and activity of glutamate 5-kinase [E.C.2.7.2.11] the enzyme catalyzing the first step of proline biosynthesis were investigated in pot experiments. Results of the experiment revealed the toxic effects of cadmium and zinc at both tested levels (2.5, 25 mg Cd and 50, 500 mg Zn o kg^-1) for spinach. Under these conditions, decrease of glutamate kinase activity in spinach plants grown on contaminated treatments compared with untreated control was found. Allosteric regulation of glutamate kinase activity by free proline creates a possibility for an increase in glutamic acid content due to the synthesis of glutathione and subsequently phytochelatines in plant cells. For this reason the rates of Cd and Zn applied into soil decreased the glutamate kinase activity. The higher doses of both metals negatively affected yield of spinach dry biomass, but only Cd dose (25 mg Cd o kg^-1 soil) was associated with the significant inhibition of aboveground biomass compared with control treatment (by 14 %). The highest contents of both elements were analyzed in blades of spinach leaves. Chlorophyll content was decreased only by higher cadmium dose.Badano zmiany metabolizmu roślin szpinaku (Spinacia oleracea L., odmiany 'Matador') eksponowanych na stres powodowany przez dwa metale ciężkie: kadm i cynk. W doświadczeniu wazonowym badano rozmieszczenie tych pierwiastków w biomasie (w korzeniach, blaszkach i ogonkach liściowych), zawartość chlorofilu oraz aktywność kinazy glutaminianowej [E.C.2.7.2.11], enzymu katalizującego pierwszy stopień biosyntezy proliny. Wyniki doświadczenia wykazały toksyczny wpływ kadmu i cynku na szpinak w obydwu zastosowanych dawkach (2,5 i 25 mg Cd oraz 50 i 500 mg Zn o kg^-1). W tych warunkach stwierdzono spadek aktywności kinazy glutaminianowej w roślinach szpinaku rosnących w obiektach zanieczyszczonych metalami w porównaniu z obiektem kontrolnych, bez ich dodatku. Regulacja allosteryczna aktywności kinazy glutaminianowej przez wolną prolinę indukuje możliwość zwiększenia zawartości kwasu glutamiowego w wyniku syntezy glutationu, a następnie fitochelatyn w komórkach roślin. Z tego względu dawka Cd i Zn zastosowana do gleby zmniejszyła aktywność kinazy glutaminianowej. Większa dawka obydwu metali ujemnie oddziaływały na plon suchej masy szpinaku, ale tylko dawka 25 mg Cd - kg^-1 gleby wywołała znaczne zahamowanie (o 14 %) wzrostu nadziemnej biomasy w porównaniu z obiektem kontrolnym. Największe zawartości obydwu metali stwierdzono w blaszkach liściowych szpinaku. Zawartość chlorofilu zmniejszyła się tylko po zastosowaniu większej dawki kadmu